Abbott Laboratories Stock News

New survey shows 40% of people living with diabetes have skipped or missed a doctor's appointment due to shame or stigma1 70% of people with diabetes said supportive comments from others can significantly boost their motivation to manage their condition1 Abbott launches film that highlights challenges of living life with diabetes ABBOTT PARK, Ill., Feb. 4, 2025 /PRNewswire/ -- 'One cupcake won'...

In the past few years, some high-profile dividend stocks have reduced their payouts, much to the chagrin of investors. As most income seekers want to avoid this fate, they might consider turning to arguably the most elite group of dividend payers on the market: Dividend Kings.

The ProShares S&P 500 Dividend Aristocrat ETF posted its 3rd worst monthly return in December, falling by 7.69%. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 42 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL.

Abbott (NYSE: ABT) recently reported its Q4 results, with revenues marginally below and earnings meeting the street expectations. The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the consensus estimates of $11.01 billion and $1.34, respectively.

On January 22, Abbott Laboratories published financial results for the fourth quarter of 2024, initially receiving mixed reactions from Wall Street. However, its revenue was about $10.97 billion for the three months ended December 31, 2024, up 7.2% year-on-year, driven by strong sales in the company's Medical Devices segment. Moreover, Abbott expects its revenue to grow by 7.5% to 8.5% in 2025,...

The outlook and technical action suggest Abbott Laboratories NYSE: ABT will lead healthcare names like Johnson & Johnson NYSE: JNJ higher in 2025. While each produced a solid quarter, Abbott Laboratories outperformed and has a more robust outlook.

The Dividend Kings underperformed the broad U.S. equity market in 2024, achieving a 5.53% total return compared to the S&P 500's 24.89%. 2024 returns for the Dividend Kings were primarily driven by earnings growth and dividends, with the change in P/E ratio being a detractor. I breakdown the components of total return for each Dividend King by sector to gain insights into current valuation.

Tariff Day has left us with Canada and Mexico in the crosshairs. With North American trade in focus, this may actually give a respite to stocks with supply chains elsewhere and light a fire under them.